Hudson T S, Carlton P S, Gupta A, Stoner G D, Morse M A
Division of Environmental Health Sciences, The Ohio State University School of Public Health, CHRI Rm. 1148, 300 West Tenth Ave., Columbus, OH 43210, USA.
Cancer Lett. 2001 Jan 10;162(1):19-26. doi: 10.1016/s0304-3835(00)00619-4.
Previous studies in our laboratory have shown that 6-phenylhexyl isothiocyanate (PHITC), enhances N-nitrosomethylbenzylamine (NMBA)-induced esophageal tumorigenesis in F344 rats while the shorter chain analogs, phenylethyl isothiocyanate (PEITC), and 3-phenylpropyl isothiocyanate (PPITC), inhibit NMBA-induced esophageal tumorigenesis. To test the hypothesis that PHITC influences the promotional stage of esophageal tumorigenesis, groups of 22-27 rats were dosed with vehicle or NMBA three times a week for 5 week, and fed a modified AIN-76A diet containing PHITC at concentrations of 0.0, 1.0, and 2.5 micromol/g. At the 25th week, the rats were killed, esophagi harvested and tumors counted. In the groups that received NMBA+PHITC, apparent but statistically insignificant increases in tumor multiplicity of 32 and 42% were found in comparison to rats treated with NMBA alone. A higher frequency of dysplastic lesions was found in rats treated with NMBA+2.5 micromol/g PHITC (71%) when compared to rats treated with NMBA only (12%). To test whether PHITC increased cellular proliferation, we evaluated proliferating cell nuclear antigen (PCNA) expression by immunohistochemistry. While there were no significant increases in PCNA staining in rats treated with NMBA+PHITC compared to rats treated with NMBA only, rats treated with PHITC only had a significantly higher PCNA index compared to untreated controls. Expression of cyclin D1, another biomarker of proliferation, was analyzed by semi-quantitative reverse transcription-polymerase chain reaction. There were no significant increases in cyclin D1 expression in groups treated with NMBA+PHITC compared to the group treated with NMBA only. Thus, while the data suggest a promotional effect by PHITC as manifested by a significant increase in dysplastic leukoplakia by the high dose of PHITC and an increase in the PCNA index by PHITC alone, PHITC does not appear to have a significant effect on esophageal cell proliferation.
我们实验室之前的研究表明,6-苯基己基异硫氰酸酯(PHITC)会增强N-亚硝基甲基苄胺(NMBA)诱导的F344大鼠食管肿瘤发生,而较短链类似物苯乙基异硫氰酸酯(PEITC)和3-苯基丙基异硫氰酸酯(PPITC)则抑制NMBA诱导的食管肿瘤发生。为了验证PHITC影响食管肿瘤发生促进阶段的假说,将22 - 27只大鼠分为几组,每周三次给予溶剂或NMBA,持续5周,并喂食含浓度为0.0、1.0和2.5微摩尔/克PHITC的改良AIN - 76A饮食。在第25周时,处死大鼠,取出食管并计数肿瘤。在接受NMBA + PHITC的组中,与仅接受NMBA治疗的大鼠相比,肿瘤 multiplicity分别有32%和42%的明显但无统计学意义的增加。与仅接受NMBA治疗的大鼠(12%)相比,接受NMBA + 2.5微摩尔/克PHITC治疗的大鼠发育异常病变频率更高(71%)。为了检测PHITC是否增加细胞增殖,我们通过免疫组织化学评估增殖细胞核抗原(PCNA)表达。与仅接受NMBA治疗的大鼠相比,接受NMBA + PHITC治疗的大鼠PCNA染色无显著增加,但仅接受PHITC治疗的大鼠与未处理对照相比,PCNA指数显著更高。通过半定量逆转录 - 聚合酶链反应分析细胞周期蛋白D1(另一种增殖生物标志物)的表达。与仅接受NMBA治疗的组相比,接受NMBA + PHITC治疗的组中细胞周期蛋白D1表达无显著增加。因此,虽然数据表明PHITC有促进作用,表现为高剂量PHITC使发育异常白斑显著增加以及PHITC单独使PCNA指数增加,但PHITC似乎对食管细胞增殖没有显著影响。